{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:44:24Z","timestamp":1774928664951,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40744-023-00605-6","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T20:40:22Z","timestamp":1697748022000},"page":"1683-1703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Hagimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Morisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Holzk\u00e4mper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6884-1557","authenticated-orcid":false,"given":"Ayako","family":"Konomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"605_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1529-8019.2008.01215.x","volume":"22","author":"DD Gladman","year":"2009","unstructured":"Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40\u201355.","journal-title":"Dermatol Ther"},{"key":"605_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2340\/00015555-1833","volume":"94","author":"K de Vlam","year":"2014","unstructured":"de Vlam K, Gottlieb AB, Mease PJ. Current concepts in psoriatic arthritis: pathogenesis and management. Acta Derm Venereol. 2014;94:627\u201334.","journal-title":"Acta Derm Venereol"},{"key":"605_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"605_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11926-012-0263-5","volume":"14","author":"WJ Taylor","year":"2012","unstructured":"Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep. 2012;14:369\u201374.","journal-title":"Curr Rheumatol Rep"},{"key":"605_CR5","unstructured":"Food and Drug Administration. TALTZ (ixekizumab) injection, for subcutaneous use. 2016. Updated March 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125521s020lbl.pdf. Accessed Apr 18, 2023."},{"key":"605_CR6","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317\u201327.","journal-title":"Lancet"},{"key":"605_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45:367\u201377.","journal-title":"J Rheumatol"},{"key":"605_CR8","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","volume":"57","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Combe B, Kremer JM, et al. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018;57:2001\u201311.","journal-title":"Rheumatology (Oxford)"},{"key":"605_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79\u201387.","journal-title":"Ann Rheum Dis"},{"key":"605_CR10","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s10067-022-06218-8","volume":"41","author":"LC Coates","year":"2022","unstructured":"Coates LC, Mease P, Kronbergs A, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. Clin Rheumatol. 2022;41:3035\u201347.","journal-title":"Clin Rheumatol"},{"key":"605_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gottlieb A, Morita A, et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis. 2019;78:1215\u20139.","journal-title":"Ann Rheum Dis"},{"key":"605_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123\u201331.","journal-title":"Ann Rheum Dis"},{"key":"605_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","volume":"7","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Sebba A, Ruderman EM, et al. Efficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study. Rheumatol Ther. 2020;7:1021\u201335.","journal-title":"Rheumatol Ther"},{"key":"605_CR14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"605_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-021-00388-8","volume":"9","author":"LE Kristensen","year":"2022","unstructured":"Kristensen LE, Okada M, Tillett W, et al. Ixekizumab demonstrates consistent efficacy versus adalimumab in biologic disease-modifying anti-rheumatic drug-na\u00efve psoriatic arthritis patients regardless of psoriasis severity: 52-week post hoc results from SPIRIT-H2H. Rheumatol Ther. 2022;9:109\u201325.","journal-title":"Rheumatol Ther"},{"key":"605_CR16","unstructured":"Acosta Felquer ML, Szentpetery A, Elmamoun M, Gallagher P, FitzGerald O, Soriano ER. Composite psoriatic disease activity index (CPDAI), defining remission and disease activity states using data from daily clinical practice [abstract]. Arthritis Rheumatol. 2016; 68(suppl 10)."},{"key":"605_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/ard.2010.129379","volume":"70","author":"A Mumtaz","year":"2011","unstructured":"Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis. 2011;70:272\u20137.","journal-title":"Ann Rheum Dis"},{"key":"605_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3899\/jrheum.140172","volume":"41","author":"PS Helliwell","year":"2014","unstructured":"Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212\u20137.","journal-title":"J Rheumatol"},{"key":"605_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2021-220964","volume":"81","author":"S Dubash","year":"2022","unstructured":"Dubash S, Alabas OA, Michelena X, et al. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Ann Rheum Dis. 2022;81:490\u20135.","journal-title":"Ann Rheum Dis"},{"key":"605_CR20","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3899\/jrheum.210662","volume":"49","author":"A Ogdie","year":"2022","unstructured":"Ogdie A, Blachley T, Lakin PR, et al. Evaluation of clinical diagnosis of axial psoriatic arthritis (PsA) or elevated patient-reported spine pain in CorEvitas\u2019 PsA\/Spondyloarthritis Registry. J Rheumatol. 2022;49:281\u201390.","journal-title":"J Rheumatol"},{"key":"605_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Sch\u00f6ls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3\u201317.","journal-title":"Ann Rheum Dis"},{"key":"605_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152134","volume":"58","author":"EE Schneeberger","year":"2023","unstructured":"Schneeberger EE, Citera G, Nash P, et al. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: a post hoc analysis of data from phase 3 tofacitinib studies. Semin Arthritis Rheum. 2023;58: 152134.","journal-title":"Semin Arthritis Rheum"},{"key":"605_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541\u201351.","journal-title":"Lancet"},{"key":"605_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15955","volume":"35","author":"M G\u00f6n\u00fclal","year":"2022","unstructured":"G\u00f6n\u00fclal M, Altunay \u0130K, Do\u011fan S, T\u00fcrkmen M, Balc\u0131 DD, \u00d6zt\u00fcrkcan S. Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: clinical data from a real-world experience. Dermatol Ther. 2022;35: e15955.","journal-title":"Dermatol Ther"},{"key":"605_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000692","volume":"4","author":"P Nash","year":"2018","unstructured":"Nash P, Behrens F, Orbai AM, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. RMD Open. 2018;4: e000692.","journal-title":"RMD Open"},{"key":"605_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476\u201388.","journal-title":"Arthritis Rheum"},{"key":"605_CR27","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar2936","volume":"12","author":"IE Adamopoulos","year":"2010","unstructured":"Adamopoulos IE, Chao CC, Geissler R, et al. Interleukin-17A upregulates receptor activator of NF-\u03baB on osteoclast precursors. Arthritis Res Ther. 2010;12:R29.","journal-title":"Arthritis Res Ther"},{"key":"605_CR28","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3389\/fimmu.2019.02925","volume":"10","author":"A Marahleh","year":"2019","unstructured":"Marahleh A, Kitaura H, Ohori F, et al. TNF-\u03b1 directly enhances osteocyte RANKL expression and promotes osteoclast formation. Front Immunol. 2019;10:2925.","journal-title":"Front Immunol"},{"key":"605_CR29","unstructured":"Eli Lilly and Company. Lilly's Taltz\u00ae (ixekizumab) now available in new, citrate-free formulation to reduce injection site pain for improved patient experience. News Release. Published August 8, 2022. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-taltzr-ixekizumab-now-available-new-citrate-free. Accessed Apr 18, 2023."},{"key":"605_CR30","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020;59:3834\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"605_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","volume":"22","author":"B Combe","year":"2020","unstructured":"Combe B, Rahman P, Kameda H, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22:14.","journal-title":"Arthritis Res Ther."}],"updated-by":[{"DOI":"10.1007\/s40744-024-00673-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000}}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00605-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00605-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T13:21:56Z","timestamp":1715865716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00605-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["605"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00605-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40744-024-00673-2","asserted-by":"object"}]},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40744-024-00673-2","URL":"https:\/\/doi.org\/10.1007\/s40744-024-00673-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideto Kameda declares consulting fees, speaker fees, honoraria, and\/or research grants from AbbVie, Asahi Kasei, BMS, Chugai, Eisai, Eli Lilly and Company, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, Taisho, and UCB. Kohei Hagimori, Yoji Morisaki, and Ayako Konomi are full-time employees of Eli Lilly Japan K.K and stockholders of Eli Lilly and Company. Thorsten Holzkaemper is a full-time employee of Lilly Deutschland GmbH. Hiroaki Dobashi is a speaker for BMS, Chugai, Eli Lilly and Company, GSK, MSD, Novartis, Pfizer, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committees at all sites where these studies were conducted and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study, and all participants consented to the publication of study results. Protocols and consent forms were approved by the institutional review board or ethics committee of each site, including the Western Institutional Review Board (SPIRIT-P1). A listing of individual sites for SPIRIT-P1 are included in the supplement of the primary manuscript []. SPIRIT-P1 was registered at ClinicalTrials.gov, NCT01695239.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}